|
Volcano Announces Schedule
of Events at the ACC 2009, Integration into Indec and Medis Software
Platforms
|
 |
 |
|
March 27, 2009 -- San
Diego --
Volcano Corporation (Nasdaq: VOLC), a leader in the development,
manufacturing and sales of products for the diagnosis and treatment
of coronary and peripheral artery disease, today announced
its presence at the 58th Annual Scientific Sessions of the
American College of Cardiology (ACC) conference in Orlando,
FL, to be held from March 29th to 31st, 2009. |
Joe Burnett, Vice President of Marketing
at Volcano commented, "Three years ago, you could flip through the ACC program and see a couple of presentations on intravascular assessment using IVUS or FFR. This year, there are more than 50 presentations, case reviews and abstracts focused on FFR, IVUS, OCT, Forward-Looking IVUS, and VH® IVUS
plaque composition. Word is getting out that more precise guidance
during PCI is important, and the sheer number of talks focused
on higher resolution tools, highlight the increased demand for
access
to these technologies. The strategy that relied on angiography
alone is evolving to include better confirmation of disease severity
and
stenting technique. The economic environment that our healthcare
system faces is demanding that we target the right patients,
and that we get it right the first time."
Volcano will be highlighting its full suite of therapy enabling technologies through live case transmissions, booth demonstrations and sales and educational partnerships. The Volcano s5i integrated imaging system will be on display at booth #3042, as well as numerous x-ray vendor booths, including GE, Philips, Siemens and Toshiba. GE will be highlighting the Innova IVUS product, which offers unique integration of the Volcano's s5i system that shares data with, and can be controlled by, the Innova system.
Volcano Corporation is also pleased to announce
that we have reached agreement with Indec Medical Systems and Medis
Medical Imaging Systems to integrate Volcano's proprietary VH® IVUS analysis technology into their IVUS image analysis software products. The integrated software is expected to allow physicians and Core Laboratories to load, display, and analyze Volcano grayscale IVUS and VH® IVUS
images and output data in a familiar file format. Prototypes of the
integrated software will be on display and available for demonstration
in Indec's booth #3248 and Medis' booth #1381 at the ACC.
About Volcano
Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices
designed to facilitate endovascular procedures, enhance the diagnosis
of vascular and structural heart disease and guide optimal therapies.
The company's intravascular ultrasound (IVUS) product line includes
ultrasound consoles that can be integrated directly into virtually
any modern cath lab. Volcano IVUS offers unique features, including
both single-use phased array and rotational IVUS imaging catheters,
and advanced functionality options, such as VH® IVUS tissue characterization and ChromaFlo®.
Volcano also provides functional measurement (FM) consoles and single-use
pressure and flow guide wires and is developing a line of ultra-high
resolution Optical Coherence Tomography (OCT) and Forward Looking IVUS
systems and catheters. Currently, more than 4,000 Volcano IVUS and
FM systems are installed worldwide, with approximately half of its
revenues coming from outside the United States. For more information,
visit the company's website at http://www.volcanocorp.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Any statements
in this release regarding Volcano's business that are not historical
facts may be considered "forward-looking statements," including statements
regarding the features, functionality and potential benefits of our
products and patient outcomes when integrated into Indec Medical Systems'
and Medis Medical Imaging Systems' IVUS image analysis software, market
awareness, acceptance and adoption of the company's technology and
growth and market development. Forward-looking statements are based
on management's current preliminary expectations and are subject to
risks and uncertainties, which may cause Volcano's results to differ
materially and adversely from the statements contained herein. Some
of the potential risks and uncertainties that could cause actual results
to differ from the results predicted are detailed in the company's
annual report on Form 10-K, quarterly reports on Form 10-Q and other
filings made with the Securities and Exchange Commission. Undue reliance
should not be placed on forward-looking statements, which speak only
as of the date they are made. Volcano undertakes no obligation to update
any forward-looking statements to reflect new information, events or
circumstances after the date they were made, or to reflect the occurrence
of unanticipated events.
A complete list of sessions can by downloaded here.
Source: Volcano Corporation
|
